Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 11
1989 5
1990 6
1991 5
1992 6
1993 7
1994 1
1995 1
1996 5
1997 4
1998 4
1999 7
2000 3
2001 4
2002 7
2003 4
2004 9
2005 10
2006 6
2007 9
2008 17
2009 14
2010 8
2011 7
2012 17
2013 27
2014 43
2015 31
2016 44
2017 41
2018 34
2019 42
2020 27
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

402 results
Results by year
Filters applied: . Clear all
Page 1
Quality of Life After Radical Cystectomy.
Tyson MD 2nd, Barocas DA. Tyson MD 2nd, et al. Urol Clin North Am. 2018 May;45(2):249-256. doi: 10.1016/j.ucl.2017.12.008. Epub 2018 Feb 21. Urol Clin North Am. 2018. PMID: 29650140 Review.
Approximately 1 in 5 new cases of clinically localized bladder cancer is muscle invasive and requires the patient to choose from 1 of 2 prevailing options for treatment: radical cystectomy or radiation to the bladder. ...Compared with the literature on other maligna …
Approximately 1 in 5 new cases of clinically localized bladder cancer is muscle invasive and requires the patient to choose from 1 of …
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. Dobruch J, et al. Eur Urol. 2016 Feb;69(2):300-10. doi: 10.1016/j.eururo.2015.08.037. Epub 2015 Sep 4. Eur Urol. 2016. PMID: 26346676 Review.
CONTEXT: The incidence of bladder cancer is three to four times greater in men than in women. ...OBJECTIVE: To review the literature on potential biologic mechanisms underlying differential gender risk for bladder cancer, and evidence regarding gender disparities in …
CONTEXT: The incidence of bladder cancer is three to four times greater in men than in women. ...OBJECTIVE: To review the literature …
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Flaig TW, et al. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. J Natl Compr Canc Netw. 2020. PMID: 32135513
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment o …
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical pr …
The Microbiome and Genitourinary Cancer: A Collaborative Review.
Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK, Sfanos KS. Markowski MC, et al. Eur Urol. 2019 Apr;75(4):637-646. doi: 10.1016/j.eururo.2018.12.043. Epub 2019 Jan 15. Eur Urol. 2019. PMID: 30655087 Review.
EVIDENCE ACQUISITION: We conducted a literature search up to October 2018. Search terms included microbiome, microbiota, urinary microbiome, bladder cancer, urothelial carcinoma, renal cell carcinoma, kidney cancer, testicular cancer, and prostate cancer. ...PATIENT …
EVIDENCE ACQUISITION: We conducted a literature search up to October 2018. Search terms included microbiome, microbiota, urinary micr …
Updates and novel treatments in urothelial carcinoma.
Hanna KS. Hanna KS. J Oncol Pharm Pract. 2019 Apr;25(3):648-656. doi: 10.1177/1078155218805141. Epub 2018 Oct 10. J Oncol Pharm Pract. 2019. PMID: 30304985 Review.
Over a decade prior to 2016, the standard of care for early disease consisted of transuretheral resection of the bladder tumor with or without intravesicular chemotherapy or immunotherapy. ...Additional updates include dose-dense gemcitabine and cisplatin for muscle-invasi …
Over a decade prior to 2016, the standard of care for early disease consisted of transuretheral resection of the bladder tumor with o …
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Boorjian SA, et al. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27. Lancet Oncol. 2021. PMID: 33253641 Clinical Trial.
BACKGROUND: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epit …
BACKGROUND: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known …
A population-based study of cardiovascular disease mortality risk in US cancer patients.
Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP, Zaorsky NG. Sturgeon KM, et al. Eur Heart J. 2019 Dec 21;40(48):3889-3897. doi: 10.1093/eurheartj/ehz766. Eur Heart J. 2019. PMID: 31761945 Free PMC article.
CONCLUSION: The majority of deaths from CVD occur in patients diagnosed with breast, prostate, or bladder cancer. We observed that from the point of cancer diagnosis forward into survivorship cancer patients (all sites) are at elevated risk of dying from CVDs compared to t …
CONCLUSION: The majority of deaths from CVD occur in patients diagnosed with breast, prostate, or bladder cancer. We observed that fr …
Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.
Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, Danjoux C, Narod SA, Nam RK. Wallis CJ, et al. BMJ. 2016 Mar 2;352:i851. doi: 10.1136/bmj.i851. BMJ. 2016. PMID: 26936410 Free PMC article. Review.
Among the patients who underwent radiotherapy, from individual studies, the highest absolute rates reported for bladder, colorectal, and rectal cancers were 3.8%, 4.2%, and 1.2%, respectively, while the lowest reported rates were 0.1%, 0.3%, and 0.3%. CONCLUSION: Radiother …
Among the patients who underwent radiotherapy, from individual studies, the highest absolute rates reported for bladder, colorectal, …
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS. Hanna KS. Drugs. 2020 Jan;80(1):1-7. doi: 10.1007/s40265-019-01241-7. Drugs. 2020. PMID: 31823332 Review.
In this article, we highlight the safety and efficacy of enfortumab vedotin for patients with advanced bladder cancer, ongoing clinical trials, clinical pharmacology, and pharmacokinetics....
In this article, we highlight the safety and efficacy of enfortumab vedotin for patients with advanced bladder cancer, ongoing clinic …
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.
Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM. Parekh DJ, et al. Lancet. 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6. Lancet. 2018. PMID: 29976469 Clinical Trial.
We aimed to compare progression-free survival in patients with bladder cancer treated with open cystectomy and robot-assisted cystectomy. ...INTERPRETATION: In patients with bladder cancer, robotic cystectomy was non-inferior to open cystectomy for 2-year progressio …
We aimed to compare progression-free survival in patients with bladder cancer treated with open cystectomy and robot-assisted cystect …
402 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page